Phase
Condition
Polymyositis (Inflammatory Muscle Disease)
Neuropathy
Sarcopenia
Treatment
Ravulizumab
Clinical Study ID
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Adult (aged ≥18 years) patients with gMG, naive to complement inhibitors, receivingravulizumab treatment in the frames of NDP in Poland.
Patients willing to participate in the study and signed Informed Consent Form (ICF).
Vaccination against N. meningitidis
Exclusion
Exclusion Criteria:
Those who plan to participate in gMG clinical trial on/after the date of firstravulizumab infusion through NDP.
Cognitive incapacity, unwillingness or language barriers precluding adequateunderstanding or cooperation.
Study Design
Study Description
Connect with a study center
Research Site
Bydgoszcz,
PolandActive - Recruiting
Research Site
Gdansk,
PolandSite Not Available
Research Site
Katowice,
PolandSite Not Available
Research Site
Krakow,
PolandSite Not Available
Research Site
Lublin,
PolandSite Not Available
Research Site
Poznan,
PolandSite Not Available
Research Site
Szczecin,
PolandSite Not Available
Research Site
Warsaw,
PolandSite Not Available
Research Site
Wroclaw,
PolandSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.